- Home
- KMI vs CADL Comparison
KMI vs CADL Comparison
Compare KMI & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMI
- CADL
- Stock Information
- Founded
- KMI 1936
- CADL 1999
- Country
- KMI United States
- CADL United States
- Employees
- KMI N/A
- CADL N/A
- Industry
- KMI Natural Gas Distribution
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- KMI Utilities
- CADL Health Care
- Exchange
- KMI Nasdaq
- CADL Nasdaq
- Market Cap
- KMI 62.2B
- CADL 252.0M
- IPO Year
- KMI 2011
- CADL 2021
- Fundamental
- Price
- KMI $28.40
- CADL $5.12
- Analyst Decision
- KMI Buy
- CADL Strong Buy
- Analyst Count
- KMI 16
- CADL 5
- Target Price
- KMI $28.25
- CADL $21.40
- AVG Volume (30 Days)
- KMI 13.0M
- CADL 923.9K
- Earning Date
- KMI 07-16-2025
- CADL 08-12-2025
- Dividend Yield
- KMI 4.12%
- CADL N/A
- EPS Growth
- KMI 5.43
- CADL N/A
- EPS
- KMI 1.16
- CADL N/A
- Revenue
- KMI $15,499,000,000.00
- CADL N/A
- Revenue This Year
- KMI $9.70
- CADL N/A
- Revenue Next Year
- KMI $4.74
- CADL N/A
- P/E Ratio
- KMI $24.56
- CADL N/A
- Revenue Growth
- KMI 1.38
- CADL N/A
- 52 Week Low
- KMI $19.68
- CADL $3.79
- 52 Week High
- KMI $31.48
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- KMI 53.44
- CADL 48.58
- Support Level
- KMI $27.88
- CADL $4.73
- Resistance Level
- KMI $29.58
- CADL $5.24
- Average True Range (ATR)
- KMI 0.63
- CADL 0.29
- MACD
- KMI 0.03
- CADL 0.00
- Stochastic Oscillator
- KMI 49.13
- CADL 64.92
About KMI Kinder Morgan Inc.
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 80,000 miles of gas, refined products, and carbon dioxide pipelines. The company also owns one of the largest portfolios of gas and refined products storage and terminals. Most of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.